°Q½×°Ï>ªYÄ£¥ÍÂå
¥«³õ­º¨£·sÃÄ ±ÂÅv½Í¤¤
·|­û:hung1201 10149413 µoªí®É¶¡:2020/6/24 ¤U¤È 02:11:23
¥«³õ­º¨£·sÃÄ(¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸) Àø®Ä¤ÀªR p=0.009

6634 ªYÄ£

ªÑ¥»: 3.832»õ

¥D­n·~°È:

¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo

¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)

¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)

Ä~Äò©¹¤U¬Ý...!

=============================================================================

²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)

¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢

²£«~Àu¶Õ:

1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«

2.¥«³õ­º¨£·sÃÄ(First-in-class)

3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x

4.µL¦w¥þ©Ê°ÝÃD

¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C

Ävª§¤O:

1.¦h­«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢

2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A­°§C¨x¯×

3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x

¬ãµo¶¥¬q:

1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á

2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ

Àø®Ä¤ÀªR¡G

1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n

2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)

=============================================================================

²£«~02¡GSNP-630

¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢

²£«~Àu¶Õ:

1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)

2.¥«³õ­º¨£·sÃÄ(First-in-class)

3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x

4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~

¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C

Ävª§¤O:

1.¦h­«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢

2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A­°§C¨x¯×

3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡

4.µL¦w¥þ©Ê°ÝÃD

¬ãµo¶¥¬q:

1.Á{§É«e

2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C

3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C

Àø®Ä¤ÀªR¡G

1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05

=============================================================================

²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)

¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)

²£«~Àu¶Õ:

1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê

2.¸Ñ¨M­¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)

3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q

¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ

Ävª§¤O:

1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«

2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^

3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O

¬ãµo¶¥¬q:

1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç

2.¤w¥Ó½ÐUSFDA¼Ï&#32445;Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D

3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç

=============================================================================

²£«~04¡GSNP-830/ SNP-840

¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B­««×¯kµh)

²£«~Àu¶Õ:

1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è

2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q

¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ

Ävª§¤O:

1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è

2.½Æ¤è¤w¥Ñ¬ü°êFDA­n¨D­°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä

3.¦³¨Ï¥Î±M§Q¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y

4.¥i¼W¥[¤AñQÓi×ô¾¯¶q

¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A­°§C¦¨Å}°Æ§@¥Î

5.¤GªÌ¾Ü¤@±ÂÅv

6.¥i¼W¥[¥«¦û²v

¬ãµo¶¥¬q:

1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç

SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ý­n¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç

µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ

=============================================================================

*****************************************************************************

SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G

1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005

1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005

=============================================================================

*****************************************************************************

¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G

1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv

2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv

3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿­±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv

=============================================================================

*****************************************************************************

¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@­p¹º

§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó

¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ù­È±o´Á«Ý¡A¦³¾÷·|¬O ¤U¤@­Ó ¦X¤@ ÄƪÑ

-----------------------------------------------------------------------------

¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)

·|­û:¤g¾|µf10147850µoªí®É¶¡:2023/2/16 ¤U¤È 01:22:58²Ä2925½g¦^À³
¦X¤@¦b2a ÁÙ¨S°µ´Nñ¤F5.3»õ¬üª÷±ÂÅv. 6919 ¤]¥´ºâ2b §¹¦¨´N ñ±ÂÅv. ¹w¦ô6-8.8»õ. ªYÄ£810 ³£¤w¦b°µ¼Ï¶s¤F. À³¸Ó¬OºÞ²zÀç¹B°ÝÃD.
·|­û:¤g¾|µf10147850µoªí®É¶¡:2023/2/16 ¤U¤È 01:11:52²Ä2924½g¦^À³
¦A¦h§Q¦h, ªÑ»ù¦u¤£¦í100.

¤£¬O¦³¤j²³¤£ª¾¹Dªº§QªÅ. ´N¬O¦ÑÁó¥u ¨I°g¬ãµo¤£¦b·NÀò§Q. ³Q¨ÖÁÊÀ³¸Ó¾÷·|´ù¯í, ¯à¦b1¦~¤º½Í ¤U±ÂÅv´N¤Ó©¯ºÖ¤F.

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/16 ¤U¤È 01:02:02²Ä2923½g¦^À³
­Jp:...§Ú¿Ë¦Û¨ìheadquarters¥h...¦Ó¥B½Í¨ì³Ì«á...»¡±z­Ì¯à¤£¯à ³o®a.§Ú´N¶R±z­ÌªºªÑ²¼°Ú.§ë¸ê±z­ÌªºªÑ²¼°Ú.¥L»¡....

§Ú¤£­t³d¥ô:À³¸Ó¬O¤j¼t¶}»ù§C¡A©Ò¥H­JP»¡¤£½æ!

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/9 ¤U¤È 08:52:57²Ä 1956 ½g¦^À³

05_·sÃĶ}µo_¿ïÃD

­J¤j¯«¦b14:15¬í°_:...½Í¨ì³Ì«á ¥L»¡±z­Ì¯à¤£¯à ³o®a.§Ú´N¶R±z­ÌªºªÑ²¼°Ú.§ë¸ê±z­ÌªºªÑ²¼°Ú...§Ú»¡ ¥xÆWªºªÑ²¼¤Ó«K©y..¹ï¤£°_ ¤£¦æ ±z­n´N¶Rcompound ±z·Q¶R[¤½¥q] §Ú­Ì¤£½æ±z....½Í¨ì³o¼Ë£²...

----------------------------------------------------------------------------------------------------

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/16 ¤U¤È 12:51:00²Ä2922½g¦^À³
2023.2.15---¹ï NASH ªº­«¤j·s¨£¸Ñ(¤@ºØÄY­«ªº¯×ªÕ¨x¯e¯f)

www.labroots.com/trending/cell-and-molecular-biology/24677/major-insights-nash-severe-type-fatty-liver-disease

...¬ã¨s¤H­û¦b¥L­Ìªº¤p¹«¼Ò«¬¤¤¨Ï¥Î siRNA °±¤î¤F RIPK3 ªºªí¹F¡C³oªí©ú¡A

[¤@¥¹ RIPK3 ¤£¦Aªí¹F¡A§Y¨Ï¦b±w¦³ÄY­«¯×ªÕ¨xªº°Êª«¤¤¡A¨x²Ó­Mªº¦º¤`©M¨x·l¶Ë¤]·|­°¦Ü³Ì§C¡C]

[¥¹ RIPK3 ¤£¦Aªí¹F¡A§Y¨Ï¦b±w¦³ÄY­«¯×ªÕ¨xªº°Êª«¤¤¡A¨x²Ó­Mªº¦º¤`©M¨x·l¶Ë¤]·|­°¦Ü³Ì§C¡C]

2023.1.23- www.nature.com/articles/s41467-023-35804-w

..§Ú­Ì³q¹L¨x²Ó­M RIPK3 ªº¥\¯à³à¥¢½T©w¤FÃa¦º©Ê­ä¤`¦bÄY­«¨x¯×ªÕÅܩʤ¤ªº­«­n©Ê¡C

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/12/17 ¤W¤È 10:30:19²Ä 2732 ½g¦^À³

¦A¤@½g²Ï¹êªº¾Ç³N¬ã¨s¡AÅýSNP610/SNP630(CYP2E1)ªºNASHÁ{§É¦¨¥\²v¤j¼W¡C

....

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/12/12 ¤W¤È 10:03:20²Ä 2709 ½g¦^À³

³Ìªñµoªíªº´X½g½×¤å...

¬ã¨sªí©ú¡ACYP2E1 ¹ï RIPK3 ªºªí¹F°µ¥X¤F­«¤j°^Äm....ªí©úCYP2E1 §@¬° RIPK3 ªº¤W´å°^ÄmªÌ...

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/16 ¤W¤È 11:12:39²Ä2921½g¦^À³
Ãø¹DJ&J¤£·|·Q¨Ó¦¬ÁʪYÄ£¡H

¦³¸Ó¤½¥q·Q­nªº¤£¶Ë¨x810

NASHªº610¤Î630

¦¬ÁÊMadrigal ­nªá¤j¿ú

¦¬ÁʪYÄ£¬Û¤ñ¥u­nªá¤p¿ú

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/16 ¤W¤È 10:25:31²Ä2920½g¦^À³
µ²½×: ±q©³¤U3½g¬ã¨s¡A±ÀÂ_JNJ-75220795¼Æ¾Ú¤£¦p¹w´Á¾÷²v°ª¡C

ARO -HSD ­°§CºÃ¦ü NASH ±wªÌªº¨xŦHSD17B13 mRNA ªí¹F©M³J¥Õ½è¤ô¥­¡C

ir.arrowheadpharma.com/static-files/b6b66255-5618-4706-96f2-e0fbfc68ce75

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/12/4 ¤U¤È 05:01:34²Ä 2705 ½g¦^À³

NASHªºµo¯f¾÷¨î¤Ó½ÆÂø¡A·sªº¬ã¨sµ²ªG¤£Â_´é²{¡AGSKªá10»õ¬ü¤¸±ÂÅvªºÃĪ«¡A¤p¹«¼Ò«¬²£¥Í¤F¤£¤@­Pªºµ²ªG¡AÁÙ¦Ûµoµo®i¬°¿ðµo©Ê¯×ªÕ¨x¡C

1. 2021.3.16 Hsd17b13 ¯Ê³´¤£¯à«OÅ@¤p¹«§K¨ü­PªÎ­D©Ê¶¼­¹·l¶Ë

www.ncbi.nlm.nih.gov/pmc/articles/PMC8627256/

2. 2022.7.16(2011¦~¿Õ¨©º¸¥Í²zÂå¾Ç¼ú±o¥DBruce Beutlerªº½×¤å)

www.nature.com/articles/s41467-022-31812-4

...³Ìªñªº¤@½g½×¤å³ø¾É¤F¤@­Ó¤£¦PªºÆ[¹îµ²ªG¡A§YHsd17b13°ò¦]ºV°£¤p¹«¦b´XºØ¯×ªÕ¨x»¤¾Éªº¶¼­¹±ø¥ó¤U¡A¦b¨x¯×ªÕÅÜ

©Ê¡B¨x·l¶Ë¡BÅÖºû¤Æ©Mª¢¯g¤è­±»P WT ¤p¹«¨S¦³®t²§!

3. 2022.1.7 (­«­n­ì³ÐªÌ:Ĭ¤å) www.ncbi.nlm.nih.gov/pmc/articles/PMC8776652/

¥O¤HÅå³Yªº¬O¡A³Ìªñ¹ï HSD17B13 °ò¦]ºV°£¤p¹«ªº¬ã¨sªí©ú¡AHSD17B13 ¯Ê¥F¯g¥¼¯à«OÅ@¨xŦ§K¨ü°ª¯×ªÕ¶¼­¹¡B¦è¤è¶¼

­¹©M°sºë¼ÉÅS¤Þ°_ªº¯×ªÕÅÜ©Ê·l¶Ë¡A³oªí©ú HSD17B13 ¯Ê¥F¯g¥i¯à¹ï¤p¹« NAFLD ¨S¦³«OÅ@§@¥Î¼Ò«¬¡C¦P¼Ë¡A¥t¤@²Õ³ø

§i»¡¡A¯Ê¥F HSD17B13 °ò¦]ªº¤p¹«¦b 9 ­Ó¤ë¤j®É¦b¥¿±`¶¼­¹¤U¦Ûµoµo®i¬°¿ðµo©Ê¯×ªÕ¨x.³o¨Ç·N·Q¤£¨ìªºµ²ªG¥Ø«e¯Ê¥F

¾÷¨î¸ÑÄÀ¡A»Ý­n¶i¤@¨B¬ã¨s¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/16 ¤W¤È 08:43:30²Ä2919½g¦^À³
J&J ¥¿¦bµo¥Í½¤ÑÂЦaªºÅܤÆ(2023.2.15ªð¦^ArrowheadªºÃĪ«±ÂÅv)¡AJ&J¥ô©R¤F¤@¦ì·sªº»â¾ÉªÌ¨Ó»â¾É¨ä»sÃĬãµo¡A§YÁɿյ᪺John Reed¡C

§Ú¤£­t³d¥ô²q´ú­ì¦]: 1.JNJ-75220795¼Æ¾Ú¤£¦p¹w´Á? 2.¹w³Æ¥X¤â¦¬ÁÊMadrigal©Îintercept?

1. 2023.2.8-- (J&J)¼b¥Í¥þ²y·~°È¤j¾ã¹y¡I 37»õ¬ü¤¸¶R¤UArrowhead B¨xÃÄ®£³Q±ó¡H

news.gbimonthly.com/tw/article/show.php?num=56115

2. 2023.2.15-- Janssen ±N I ´Á NASH(JNJ-75220795)­Ô¿ïÃĪ«ªð¦^ Arrowhead

www.fiercebiotech.com/biotech/jj-strikes-down-nash-pact-arrowhead-hep-b-deal-still-limbo

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/11/29 ¤U¤È 05:37:52²Ä 1489 ½g¦^À³

¬d²z.»X®æ:°ªÃBªº³ø¹S¨Ã«D¨Ó¦Û©ó¶R½æ¡A¦Ó¬O¦s¦b©óµ¥«Ý¤§¤¤¡C

2020.12.22 ªYÄ£»P°ê»ÚÃļtñSNP-810¬ãµo¦X§@¨óij

VS

2018.10. 04 Arrowhead »P Janssen ¹F¦¨ 37 »õ¬ü¤¸ªº³\¥i©M¦X§@¨óij

(JanssenÀò±o3­Ó¦X§@¶µ¥Ø:ARO-JNJ1 ;ARO-JNJ2;ARO-JNJ3)

ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-enters-37-billion-license-and-collaboration-agreements

¸g¹L 1¦~2¦~3¦~

2021 ¦~ 1 ¤ë 17 ¤é-- Arrowhead¤µ¤Ñ«Å¥¬¨ä¦X§@ªÌ¡A ·¨´Ë»sÃĤ½¥q, (Janssen) ±j¥ÍºX¤Uªº Janssen »sÃĤ½¥q¤§¤@¡A¤w©ÜÅS»P Arrowhead ´N¬ã¨s¤Æ¦Xª« JNJ-75220795 ªº¦X§@

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2023/2/15 ¤U¤È 01:31:33²Ä2918½g¦^À³
±q¼ÖÆ[¨¤«×¬Ý¡A¤µ¦~¦X§@¨óij¤w²Ä3¦~¤F¡A¬O¥i¯à±ÂÅv®×ñ©wªº¡C810³B¤è«D³B¤è¥þ²y¥[Á`3»õ¬ü¤¸¸¨«Ë»ù¡A¦X²zªÑ»ù¬O600¤¸¡A©¡®É¯u¥¿ªÑ»ù´N¬Ý¥«³õ»{©w¡C
·|­û:¤g¾|µf10147850µoªí®É¶¡:2023/2/14 ¤U¤È 09:18:12²Ä2917½g¦^À³
§Ú­Ó¤H·Pı¶¶§Qªº¸Ü: 2024 Q2 ¥H«á8¨t¦C¦³¾÷·|±ÂÅv¦¨¥\.
·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/14 ¤U¤È 04:20:56²Ä2916½g¦^À³
R¤j

¸g¸ß°Ý¥DºÞ¾÷Ãö¡A®Ö­ã¸ÕÅç®×¥ó§¡µn¸ü©ó»OÆWÃĪ«¸ÕÅç¸ê°Tºô¡C

¸Óºôµn¸üªº²Ä¤@¶µ¦h¾¯¶q¸ÕÅç36¤H¦Ü2023¦~12¤ë31¤é¤î¡C

±©¸Óºô­¶Áöµn¸ü¬°¡u¦h¾¯¶q¡v¡A«o¶È¦³500²@§J¡u³æ¾¯¶q¡v¡C

¨Ã¥¼µn¸üÄÝ©ó4-8§J¤§¨ä¥L¾¯¶q¡A¡u¦h¾¯¶q¡v¡B¡u³æ¾¯¶q¡v©úÅ㤣²Å¡C

¡u¥l¶Ò¤¤¡v

­Ó¤H±À´ú¬O¦P¤@­Ó¸ÕÅç

¥t610-2¤]¸ò¤W¤S¤U¬[ºô­¶®É¶¡¤@¼Ë¦Ü114¦~¡A¤H¼Æ80¤H¡C

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/14 ¤W¤È 09:50:21²Ä2915½g¦^À³
´Nºâ³o¬O810¦b¥xÆWªº¼Ï¯Ã(¤H) §Úı±o2¤j¼tÁÙ¬O¤£·|¶R³æ ¥¦ªù­n¬Ýªº¬O¬ü°ê¼Ï¯Ã

¡X¡X¡X¡X

¨â¤j¼t¥»´N¦³Ã±¦X§@¦X¬ù-¸ÕÃÄ®Ä

A¤½¥qÃĮĸÕÅç¤w³q¹L

B¤½¥q¦X¬ù¨ì´Á¡A¥¼§¹¦¨ÃĮĸÕÅç¡C

¨º¤Ñ¤W¤S¤U¬[ªººô­¶

¦³B¤½¥q¥¿¦b¶i¦æÃĮĽT»{

³B¤èñªº¼Ï¶s¹LÃö

­Ó¤H»{¬°»ù­È¬OOTCÃÄÃÒ©Ò¤£¯à¤ñ

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/14 ¤W¤È 08:49:09²Ä2914½g¦^À³
¯È¤j

¬ü°ê¼Ï¶s¸ÕÅç¬O³æ¾¯¶q

­ì¥Ó½Ð¤ñ¼Ð·Ç¾¯¶q°ª

«á¨Ó¬ü­n¨D¤j¹«¸ÕÅç

¤½¥q¥¼ÁקK¼vÅT¸ÕÅç

¦n¹³§ï¬°¼Ð·Ç¾¯¶q

¥u­n»OÆW¼Ï¶s¹LÃö

±ÂÅv´N¦n½Í¡A¬ü¸ÕÅç¤]·|§ó¶¶§Q¡C

·|­û:¯È¤W´I¶Q10134993µoªí®É¶¡:2023/2/14 ¤W¤È 12:52:14²Ä2913½g¦^À³
¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸

---------------------------------------

§Ú¤@ª½Ä±±o ¨ä¹ê³o´N¬O¦bÁ¿ª¯ªº¹êÅç ±Ô­z¤£²M ³æ¦ì¥Î¿ù

´Nºâ³o¬O810¦b¥xÆWªº¼Ï¯Ã(¤H) §Úı±o2¤j¼tÁÙ¬O¤£·|¶R³æ ¥¦ªù­n¬Ýªº¬O¬ü°ê¼Ï¯Ã

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/13 ¤U¤È 08:11:14²Ä2912½g¦^À³
R¤j

³o¨Ç±Ô­z¬O¤½¥q¨º¤Ñ¤W¬[¨S¦h¤[¤S¤U¬[ªº¤º®e

¨º®É±z¤]po¤F¥ÎÃÄ7¤Ñªº¸ê°T

¨ì©³¬O¤°»ò¡H­n°Ý¦¶¸³¡I

¤S¬°¤°»ò¤S¤U¬[¡H

¬O¤£¬O¥h¦~³o­Ó¤½§i¸ÕÅçµ²ªG¡I

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/13 ¤U¤È 03:23:28²Ä2911½g¦^À³
·|­û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/12 ¤U¤È 08:40:35²Ä 2909 ½g¦^À³

....810ªº¼Ï¶s¸ÕÅç¡A±q¡u¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸¡v¡u¥ÎÃÄ7¤Ñ¡A¤£¶Ë¨x¡Aµ²ªG²Å¦X¹w´Á¡v

¡u¸ÕÅç³ø§iÄ¡¼g¤¤¡vµ¥µ¥¡A±À¦ô¼Æ¾Ú¥¿¦V¡A·¥¦³¾÷·|¦bµu´Á¶¡¤º¤½§iµ²ªG¡C

------------------------------------------------------------------------------------------------

¤W­±À³¸Ó¬O«ü111/10/20ªº¤½§i:

1.¨Æ¹êµo¥Í¤é:111/10/20

2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¸ÕÅçÄݩ󥻤½¥qSNP-810[¼Ï¯Ã©ÊÁ{§É]ÅçÃÒ¸ÕÅ礧¤@¡A¸ÕÅç³]­p¬O¦h¾¯¶q¡B³æª¼¡B³æ¤¤¤ß

¤Î¤fªAµ¹»P´¶®³¯k©ÎµL¨x¬r©Ê¤îµh·sÃÄSNP-810¤§Á{§É¦w¥þÅçÃÒ¸ÕÅç¡A§ë»P¾¯¶q4-8§J¡A

¸Ó¸ÕÅ羯¶q¤w¶W¹L²{¦æ¤AñQÓi×ô(Acetaminophen)ÃÄ«~»¡©ú®Ñ®Ö­ã¨Ï¥Î¨C¤é³Ì¤j¾¯¶q¡A

¹w­p§¹¦¨36¦ì¨ü¸ÕªÌ¡A¨ú±oÁ{§É¦w¥þµ²ªG«á¡A¦A¦V½ÃºÖ³¡­¹Ãĸp¿Ô¸ß·sÃĮ֭ã¤W¥«¡C

--------------------------------

(§Ú¦b¥xÆWÃĪ«Á{§É¸ÕÅç¸ê°Tºô¬d¤£¨ì36¦ì¨ü¸ÕªÌªºÁ{§É?)

·|­û:¤g¾|µf10147850µoªí®É¶¡:2023/2/12 ¤U¤È 10:32:05²Ä2910½g¦^À³
ÁÂÁ¦V«e¤j¤ÎROGER5889¤jªº¸Ñ»¡. ·U¨Ó·U¤F¸Ñ»Ùê¦b¨º¸Ì. ³o¼Ë¬Ý610­n±ÂÅvÁÙ»·ªº«Ü. §Y¨Ï2¢ê¹L, ÁÙ¦³°Æ§@¥Î°ÝÃD.

²{¶¥¬q´Á«Ý810±ÂÅv¤ñ¸û°È¹ê.§Ú¬Ý3¤ë¥Ó½ÐIPO¤WÂd¡AÀ³¸Ó¾÷²v¤£¤j¡D¨S¦n»ù¿ú¡D

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/12 ¤U¤È 08:40:35²Ä2909½g¦^À³
¤½¥q¹ï©ó610ªº¸ÕÅç¼Æ¾Ú¡A¥u¤½¥¬Àu¶Vªº¼Æ¾Ú¡A¨Ã¨S¦³¤½¥¬°Æ§@¥Î¡C

¥Ø«eNASH·sÃĸÕÅç¡A´X¥G³£¦³°Æ§@¥Î¡C

I¤½¥q¬J¨Ï3´Á¹F¼Ð¡A¥Ñ©ó°Æ§@¥Î¤Ó¤j¡A¥Ó½ÐÃÄÃÒ³Q»é¦^¡C

M»PA¤½¥q¤]³£¦³°Æ§@¥Î¡A¤j®aÃIJz¾÷Âà´X¥G¬Û¦ü¡A¬G±À610¤]¨ã¦³¦P¼Ë°ÝÃD¡C

630°µ§¹1´Á¡AºÙ¨S¦³°Æ§@¥Î¡A¤½¥q¥»¨Ó¥i¯à­p¹º¥H610ÅçÃÒÃĮīá­n¥D§ð630¡AµL©`¦X¦¨§xÃø¡A¦¨¥»¤Ó°ª¡A¦h¦~¥H¨Ó¡AµLªk¸Ñ¨M¦X¦¨¦¨¥»ªº°ÝÃD¡C

­ì±ÀM¤½¥q3´Á­n¨ì2024¦~¡A¤£±o¤£¤Ï¹L¨Ó¥ý°µ610¡A¤~¯à»°¤W«e´X¦W¡A¦]¤j®a§¡¨ã°Æ§@¥Î¡A³o´Á¶¡¦A´M¨D630¦X¦¨°ÝÃD¡A§ä¨ì¤èªk«á¦A°µ630ªº2´Á¡C

³o¥i¯à¬ON¤j©Ò»¡ªº¥dÃö¡H

810ªº¼Ï¶s¸ÕÅç¡A±q¡u¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸¡v

¡u¥ÎÃÄ7¤Ñ¡A¤£¶Ë¨x¡Aµ²ªG²Å¦X¹w´Á¡v

¡u¸ÕÅç³ø§iÄ¡¼g¤¤¡vµ¥µ¥¡A±À¦ô¼Æ¾Ú¥¿¦V¡A·¥¦³¾÷·|¦bµu´Á¶¡¤º¤½§iµ²ªG¡C

¦pªG¼Ï¶s¸ÕÅçµ²ªG¡A¥¼¦b3¤ëªì¤½§i¡A«hIPO·|©µ«á¡Aµ¥¨ì¼Ï¶s¹LÃö«á¦A­«·s¥Ó½Ð¤u·~§½°ª¬ì§Þ¦P·N¨ç¡C

¼Ï¶s¸ÕÅç¹LÃö¡A¦A½Í±ÂÅv»ù½X¤~·|°ª¡C

¥H¤W¬O­Ó¤H¬Ýªk¡A¶È¨Ñ°Ñ¦Ò¡I

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/12 ¤U¤È 05:35:38²Ä2908½g¦^À³
¤£ª¾¹D2®a©e°U¦X¦¨»PÀu¤Æ¦³µL¬ð¯}?

SNP-610²{°µªºP2¬dÅçµn°O¥ÎÁ{§É¡A¤£¬O­«§@¤G´Á!

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/25 ¤U¤È 06:13:11²Ä 2543 ½g¦^À³

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 09:52:26²Ä 2236 ½g¦^À³

¦³¤Ö¼Æ¤p¤À¤lÃĦX¦¨¨BÆJ¦h¥B²£²v·¥§C¡A¦¨¥»°ª©ó¤j¤À¤lÃÄ!(SNP-630«ÜÃø¦X¦¨!!!)...

--------------------------------------------------------------------------------------

1.©e°U¬ã¨s °]¹Îªk¤H¤¤µØ´º±dÃľǰòª÷·|110/5/1~111/4/30 SNP-630ÃÄ«~¤Æ¦Xª«(¦X¦¨Àu¥ý)©e°U§Þ³NªA°È

2.©e°U¬ã¨s »OÆW¤j¾Ç 110/7/1~111/6/30 SNP-630¦X¦¨ÃÄ«~¬ã¨s­pµe®Ñ

SNP-630«ÜÃø¦X¦¨¬OÁô¼~¡A§Æ±æ¦³¬ð¯}!

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:24:48²Ä 2160 ½g¦^À³

¬Ý¬Ý¯E¹©¡ASNP-630¦¨¥»¬OÁô¼~?!

·|­û:Ntumgk10151447µoªí®É¶¡:2023/2/12 ¤U¤È 05:14:13²Ä2907½g¦^À³
¤j®a¤@ª½Ãöª`610¡A­Y¥L¨º»ò¦n¡A¦b810¬ü°ê¼Ï¯Ã¸ÕÅç¥dÃö®É¡A¬°¦ó¤§«e·|»¡­n¥þ¤O½Ä¨ë630¡H

­«¥Ó630¦w©w©Ê»P¦¨¥»©|«Ý¸Ñ¨M¡A²{¦b610¤S­n°õ¦æ2b¤F¡H»¡¥Õ¤F¤]¬O¥dÃö

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/12 ¤U¤È 05:09:34²Ä2906½g¦^À³
SNP-810 = SNP820(CYP2E1§í¨î) + APAP

SNP-610/SNP-630(CYP2E1§í¨î+DGAT1§í¨î)

°£¤FAPAP¸Ñ¬r¡A§Æ±æ¦³Ãļt¦³¿³½ì¶}µoSNP820¦b¤ß¦åºÞ¯e¯f(DCM...)»P¸£¯«¸g¯e¯f(©¬ª÷´Ë¤ó¯g/ªü¯÷®üÀq¯g...)Á{§É!

-------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2023/2/6 ¤U¤È 12:01:05²Ä 2846 ½g¦^À³

CMZ can only be given for a short period of time and therefore other CYP2E1 inhibitors to treat ALD are needed.

CMZ can only be given for a short period of time and therefore other CYP2E1 inhibitors to treat ALD are needed.

.

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2023/2/12 ¤U¤È 04:25:41²Ä2905½g¦^À³
ªYÄ£6¨t¶i«×ÁöºC«Ü¦h¡I¦ý¥¦ªº½T¬OÀu¨q¡A¥HÀø®Ä¼Æ¾Ú¹ï¤ñ3196¬O¦n¤W3­¿¡A29¤ñ8¡Fa©M3196³£¨S¦³§Ö³t¡B¬ð¯}»{©w¡A¦Ó630©M810³£¹w©w­n¥Ó½Ð¡A¯à¤£¯à¹L¬O¥¼ª¾¦ý¦Ü¤Öªí¥ÜÀu¶V©Ê¡C¤½¥q¬ãµo¶i«×­pµeªÅ¥Õ«áÁ`¬O¦³¤@¤Ñ­n¶K¥X¡A§Ú²q·Q¶i«×·|¦A´£«e¤@¨Ç¡A­ì­pµeºâ¥X©_ªººC¡C
·|­û:¤g¾|µf10147850µoªí®É¶¡:2023/2/12 ¤U¤È 02:04:42²Ä2904½g¦^À³
¦pªG§Úªº¬Ýªk¿ù»~, ½Ð¤j®a«ü¥¿:

1. 610 2a­«°µ©Î¸É°µ, ¥[¤W2b¥i¯à­n3-5¦~.

2. 610Á{§É2´Á§@§¹«e«ÜÃø§ä¨ì±ÂÅv.

3. ±ÂÅv¥i¯à¥u³Ñ8¨t¦C.

4. 8¨t¦C¥«³õ³W¼Ò¤Î»ù­È»·§C©ó6¨t¦C.

§Ú­ì¥»§ë¸ê¶R¶i¬O»{¬°:

1. 1¦~¤º¦³¾÷·|½Í¦¨8¨t¦C±ÂÅv.

2. 2¦~¤º6¨t¦CÁ{§É2¥i§¹¦¨.

²{¦b±¡¶Õ, ¤j®a»{¬°¸ÓÄ~Äò¶R¶i¶Ü? ÁÙ¦³ºô¤Í»{¬°¥i¼Ú¦L¶Ü?

§Ú­ì¥»¶R¶i®É¥´ºâ«ù¦³2¦~, ²{¦b¬Ý¥i¯à¸Ó3-4¦~.

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2023/2/12 ¤U¤È 01:39:38²Ä2903½g¦^À³
¬Ý¨ìªYÄ£°Ýµª¶°¡G610¦¨¥\´£¨Ñ630¦¨¥\«O»Ù¡C³o¡q«O»Ù¡r¦r²´¤ñ§Ú»{ª¾¦¨¥\¾÷²v°ª§ó±j¯P¡Bí©w·P¡C²³æ»¡´N¬O6¨t¨âÃÄ®§®§¬ÛÃö¡A610¬O«e±´Ãįন¥\630¤~¯à¦¨¥\¡F¤Ï¤§¥ç¬O¡C©Ò¥H¥i¥H¸ÑŪ630³o¤jÃĪá¿úµ¹®É¶¡´N¯à¦¨¥\¡A¤£¯à»¡¦Ê¤À¦Ê¦ý¬O«Ü±µªñ¡CÂÔ¦¹´£¨Ñ­Ó¤H²L¨£¬Ýªk¡C
·|­û:ROGER588910148151µoªí®É¶¡:2023/2/12 ¤W¤È 10:28:24²Ä2902½g¦^À³
¦³ÂI·N«äªº[ÅK¦º¤`]ÃöÁp!(AA=ªá¥Í¥|²m»Ä)

SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[:¤@¥¹ CYP2E1 ³Q§í¨î¡A¨xŦ¤¶¾Éªº CYP2E1 ¤º·½©Ê¥NÁª«¡]¥]¬A LysoPC 22:4¡BDHA¡BAA ©M LCA¡^ªº¥NÁ´N·|´î®z¡A±q¦Ó¨Ï³o¨Ç¤Æ¦Xª«¦b¨x²Ó­M¤¤¼W¥[!

¤t¤j团队报¹D脑¯Ê¦å¦AÄéª`¤¤¾®¦å酶诱导ACSL4¨Ì赖©Ê铁¦º¤`

k.sina.com.cn/article_5803416260_159e91ac4019011n89.html

®ñ¤Æ应¿E¡C随þÓROS¤É°ª¡A§Ü®ñ¤Æ剂¨t统ªº¨¾±s¯à¤Oú£®z¡A§Ü®ñ¤Æ剂酶¥¢¬¡©M§Ü®ñ¤Æ剂®ø¯Ó¡C这会导­P¦hÏú¦³®`¨Æ¥ó¡A¨Ï¯«经¤¸­ä¤`©M§¥¦º¡C¡@¡@这´N¬O为¤°¤\针对®ñ¤Æ应¿E¬O¤@Ïú¦X²zªºªv疗¤èªk¡A¯S别¬O¡A铁¨Ì赖©Êªº铁¦º¤`³q过过¶qªº¯×质过®ñ¤Æ导­P细­M¦º¤`¡A这¥i¯à导­P脑¨ò¤¤¤¤¯«经¤¸ªº¦º¤`¡C

.....

§@ªÌ§Q¥Î¯×质¥N谢组学¡B³J¥Õ质组学©M§K¬Ì组¤Æµ¥¤â¬q¡A

发现¾®¦å酶¤Î¨ä[ªá¥Í¥|²m»Ä][ªá¥Í¥|²m»Ä][ªá¥Í¥|²m»Ä]¥N谢¤U´åªºACSL4]¬O参ÉOI/R¤¤铁¦º¤`诱导ªº细­M¦º¤`³q¸ô¤¤ªº关键³J¥Õ¡]图1¡^¡A从¦Ó对¯Ê¦å©Ê脑¨ò¤¤铁¦º¤`ªº¥Íª«学Éó¨î¦³¤F·sªº认识¡A该³q¸ô¥i¯à为ªv疗¯Ê¦å©Ê脑¨ò¤¤´£¨Ñ·s³~径¡C

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³

ªYÄ£¥²­nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/12 ¤W¤È 08:29:28²Ä2901½g¦^À³
2022.9.16--Front. Neurosci|¯«经°h¦æ©Ê¯e¯f¬ã¨s·s¤è¦V¡GNrf2©M铁¦º¤`

m.medsci.cn/article/show_article.do?id=7177291544ec

....

[铁¦º¤`]¬O¤@Ïú¥Ñ¨Ì赖¤_[ROS]©M细­M内铁¶W载ªº[¯×质过®ñ¤Æ§@¥Î]¤Þ°_ªº·sªº独¯Sªºµ{§Ç©Ê细­M¦º¤`§Î¦¡¡A¦ý¨ä许¦h¥Í²z§@¥Î©|«Ý©úÚÌ¡C¥Ø«e¤w经¦³¨¬û{ªº证Õuªí©ú¡A¦b¯«经°h¦æ©Ê¯e¯f´Á间ÚÌ实发¥Í¤F铁¦º¤`¡A¦}¥B³q过¹v¦V铁¦º¤`ªº调节剂ªv疗¯«经°h¦æ©Ê¯e¯f¤w³Q证©ú¬O¥i¾aªº¡C

---------------------------------------------------------------------------------------------------

Q&A:¶Q¤½¥qªº¯×ªÕ¨xª¢ÃĪ«¦³¦ó¯S®í¤§³B¡H

SNP-6¨t¦C¤£¶È¨ã¦h­«¾÷Âà¡A§ó¥i¤À§O°w¹ï¥H¤U¤T¤jÃþ¾÷ÂàªvÀø/¹w¨¾¯×ªÕ¨xª¢¬ÛÃö¯f¯g¡G

(1) ½Õ±±¨x¯×ªÕ¥NÁÂ

(2) §Ü¯×ªÕ¨xª¢

SNP-6¨t¦C¥iª½±µ§í¨î¨xŦCYP2E1¬ÛÃö»Ã¯À¡B­°§CCYP2E1¬ÛÃö°ò¦]ªºmRNA©M³J¥Õªí²{¶q¡A¨Ï±o·|¶Ë®`¨x²Ó­M¡B»¤µoµoª¢¤ÏÀ³ªº¬¡©Ê®ñ¤Æª«½è(Reactive oxygen species, ROS)¤£¦A²£¥Í©Î­°§C¡A¶i¦ÓªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/11 ¤U¤È 11:06:39²Ä2900½g¦^À³
2022.10.20---ÅK¦º¤`´¦¥Ü¾÷¨î©MªvÀø¨x¯fªº¾÷·| file:///C:/Users/USER/Downloads/cells-11-03301.pdf

[ÅK¦º¤`]©MAPAP(¹ï¤AñQÓi×ô)»¤¾Éªº«æ©Ê¨x·l¶Ë

...GSH¤U­°¡BÅK¹L¸ü©M¯×½è¹L®ñ¤Æ³Q»{¬°¬O°ò¥»ªºAPAP ¤Þ°_¨x·l¶Ëªº¾÷¨î¡C¶V¨Ó¶V¦hªº¬ã¨s¤H­û¤w¸gÃÒ¹êÅK¦º¤`°Ñ»P APAP »¤¾Éªº²Ó­M¦º¤` ..... Á`¤§¡AÅK¦º¤`¥i¯à¦b APAP »¤¾Éªº«æ©Ê¨x·l¶Ë¤¤µo´§­«­n§@¥Î¡A§ó¦n¦a¤F¸ÑÅK¦º¤`ªº½Õ¸`§@¥Î¥i¯à´£¨Ñ¼ç¦bªºÁ{§ÉªvÀø¤èªk¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/11 ¤U¤È 10:47:57²Ä2899½g¦^À³
CYP2E1 ¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö­«­nªº§@¥Î?

¦Û2012¦~[铁¦º¤`]¤@词³Q´£¥X¥H来¡A[铁¦º¤`]¤Þ°_¤F¤H们ªºÆΪx关ª`¡C(¤@Ïú·sªºªüûدý®üÀq¯f°²说)

1.Nature综­z|铁¦º¤`¦b¯e¯f¤¤ªº发¯fÉó¨î¡B¥Íª«学©M§@¥Î

m.ebiotrade.com/Newsf/2021-10/20211022070102716.htm

2.2022.3.26-­«½S综­z¡I铁¦º¤`¦b©¬ª÷´Ë¯f¤¤ªº§@¥Î news.bioon.com/article/f7cde232405a.html

©¬ª÷´Ë¯f(PD)¥H¦h¤ÚÓi(DA)¯à¯«经¤¸丢¥¢©M­M浆³J¥Õ¥]²[Ê^§Î¦¨为¯S©º¡C尽ºÞ©¬ª÷´Ë¯fªºṲ́Á发¯fÉó¨î©|¤£²M·¡¡A¦ý铁

¥N谢¯¿乱¤w³Q认为¬O¤@个ýͦbªº­P¯f¦]¯À¡C·sªº证Õuªí©ú¡A¯«经胶质细­Mªº¿E¬¡¦b铁¦º¤`©M随¦Zªº¯«经°h¦æ©Ê变¤¤°_þÓ关

键§@¥Î¡C

3. 2021.9.30-铁¦º¤`ªº发¥ÍÉó¨î©M¬ã¨s«ä¸ô¬O¡H

www.cn-healthcare.com/articlewm/20210930/content-1269610.html

¬ã¨s­I´º:铁¦º¤`¬O铁©M¬¡©Ê®ñ¡]ROS¡^¨Ì赖©Êªº调节©Ê细­M¦º¤`§Î¦¡¡A¬O¤£¦P¤_细­M­ä¤`¡B细­M§¥¦º¡B细­M¦Û¾½ªº·s«¬细

­M¦º¤`¤è¦¡¡C

铁¦º¤`发¥ÍÉó¨î:铁¦º¤`ªº发¥Í¬O细­M内¯×质¬¡©Ê®ñ¡]ROS¡^¥Í¦¨ÉO­°¸Ñªº¥­¿Å¥¢调©Ò­P¡C

4.铁¥¢¿Å©M铁¦º¤`¡G¥i¯à¬O¤@Ïú·sªºªüûدý®üÀq¯f°²说 zhuanlan.zhihu.com/p/488318042

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/23 ¤U¤È 10:48:06²Ä 2256 ½g¦^À³

ªñ¦~¨Ó¡A²Ó­M¦â¯À P450 酶 (CYP) ªº­«­n©Ê¤w¶W¥X¨ä¦b¨xŦ¤¤ªº§@¥Î???

CYP2E1 ¬O¤@ºØ¤½»{ªº°Ñ»P¦UºØ¤º·½©Ê©M¥~·½©Êª«½è¥NÁªº³æ¥[®ñ酶¡A¦b¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö­«­nªº§@¥Î¡C

CYP2E1ªº [¹Lªí¹F]¦ü¥G¹ï¦h¤ÚÓi¯à¯«¸g¤¸¦³®`....

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/11 ¤U¤È 08:12:28²Ä2898½g¦^À³
CYP2E1§í¨î-->¿E¬¡ PPAR£\-FGF21

±EÀu?(SNP-610/SNP-630²æ¹v?)

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³

ªYÄ£¥²­nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C

2022.5¤ë www.sciencedirect.com/science/article/pii/S2211383522000545

¥Ñ©ó CYP2E1 ¥D­n¦b¥D­nµo¥Í¥NÁªº¨x²Ó­M¤¤ªí¹F¡A¹v¦V§í¨î CYP2E1 ¥i¯à¹ê²{­ì¦ì¨x²Ó­M¤¤ªº PPAR £\¿E¬¡¡A³o¥i¥HÁ×

§KÁ{§É¤¤°¸º¸µo¥Íªº«D²Õ´¯S²§©Ê PPAR £\¿E¬¡ªº°Æ§@¥Î--->SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂)

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/11 ¤U¤È 08:04:45²Ä2897½g¦^À³
±EÀu???

®ü¥Í¬ì°|µ¥发现FGF21¦b缓¸Ñ内质ÊI应¿EÉO¯×ªÕ¨x¤¤ªº§@¥Î¤ÎÉó¨î (AkeroªºEfruxifermin¬OFGF21Ãþ¦üª«) www.cas.cn/ky/kyjz/201411/t20141119_4255383.shtml

MadrigalªºResmetirom(THR-£]¿E°Ê¾¯)¬OF2~F3¨úÃÒ¡AF4¥[ºòÁ{§É¸ÕÅ礤!

---------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/12/21 ¤U¤È 03:26:06²Ä 2745 ½g¦^À³

...«ö¥Ø«e¼Æ¾Ú¡A²Ä1¤ä¦b«D¨xµw¤ÆF2~F3 »P¨xµw¤ÆF4¤jº¡³e¨úÃÒªº¬OAkeroªºEfruxifermin¾÷²v¸û¤j¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/11 ¤U¤È 07:47:19²Ä2896½g¦^À³
¿Õ¨©º¸¼ú¯Å¬ã¨s¡§¤º½èºôÀ³¿E¤ÏÀ³¡¨ --阐©ú该Éó¨îªº¤é¥»¬ã¨s¤H员³Q视为诺贝ûØ奖­Ô选¤H(2014¦~ýU获¬ü国©Ô´µ§J奖)¡A该Éó¨î¤]³Q视为¦³«e´ºªºªv疗¹v点¦Ó备¨ü瞩¥Ø¡C

Cyp2e1¡A¥D­n¤À§G¦b²É½uÅ餺½¤©Î¬O¤º½èºô¤W¡C¨x²Ó­M¤º¦s¦b¤j¶qªº¤º½èºô¡A³\¦h¨xŦ¬ÛÃö¯e¯f§¡»P¤º½èºôÀ³¿E¦³Ãö¡C

CYP2E1¬O²£¥ÍROS(®ñ¤ÆÀ³¿E)³Ì¥D­nªºCYP¨È«¬¡C

1.2022.11.14诺奖级¬ã¨s¡§内质ÊI应¿E¤Ï应¡¨¡Aªì创¥ø业ºË­ã临§É试验

www.keguanjp.com/kgjp_keji/kgjp_kj_smkx/pt20221114000002.html

将¡§内质ÊI应¿E¤Ï应¡¨¥Íª«Éó¨î¥Î¤_药ª«开发ªº¬ã¨s¥¿¦b±À进¤§¤¤¡C¤é¥»ªºªì创¥ø业计¦E¤_2024¦~开©l针对¿}§¿¯f©M¯«经¨t

统ºÃ难¯e¯f进¦æ临§É试验¡C¬ã¨sªí©ú¡A现¦³药ª«ªº§@¥Î¤]ÉO内质ÊI应¿E¤Ï应Éó¨î¦³关¡C阐©ú该Éó¨îªº¤é¥»¬ã¨s¤H员³Q视为

诺贝ûØ奖­Ô选¤H¡A该Éó¨î¤]³Q视为¦³«e´ºªºªv疗¹v点¦Ó备¨ü瞩¥Ø¡C

内质ÊI¦b细­M¤¤¥R当¦X¦¨³J¥Õ质ªº¤uÉD¡C¦pªG³J¥Õ质ªº¡§¦¸«~¡¨²Ö积产¥Í¡§应¿E¡¨¡A会诱导­×Î`©Î¥h°£该³J¥Õ质ªº¡§¤Ï应¡¨¡C¨Ê

³£¤j学´Ë©M«T±Ð±Â阐©ú¤F¤W­zÊ^内³J¥Õ质«~质ªººÞ²zÉó¨î¡A¦}¤_2014¦~ýU获¬ü国©Ô´µ§J奖¡A该奖项³Q视为诺贝ûØ奖ªº风¦V

标¡K¡K

2.¤º½èºô¹v¦V§í¨î CYP2E1´î»´¨x²Ó­M®ñ¤ÆÀ³¿E©M°fÂà°sºë©Ê¨x¯f(CMZ@ER-NEs纳¦Ì§Þ术)

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/10/30 ¤W¤È 10:55:32²Ä 2648 ½g¦^À³

2022.8.31µØªF5¤j¦W®Õ®ý¦¿¤j¾Ç³Ì·s¬ã¨s¡GCMZ@ER-NEs纳¦Ì§Þ术¦³±æ°f转°sºë©Ê¨x¯f

www.toutiao.com/article/7138028614150423055/

3.2021.9.22 ©¬ª÷´Ë¯fªº·sÃĪ«¹vÂI: ¤º½èºô(ER)À³¿E½Õ¸`¾¯

content.iospress.com/articles/journal-of-parkinsons-disease/jpd212673

4. html.rhhz.net/GJSJBX/2014-2-164.htm

内质ÊIÉO线²ÉÊ^¥\¯à

内质ÊIÉOROS (®ñ¤Æ应¿E)

5.CYP2E1 ¦b¸£¤ºÃĪ«¥NÁ©Υͪ«¿E¬¡¤¤ªº§@¥Î

www.ncbi.nlm.nih.gov/pmc/articles/PMC5259652/

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/11 ¤W¤È 07:52:00²Ä2895½g¦^À³
ÁÂÁªY¤jªº¸¨¤é±ø´Ú¸ê°T¡C
·|­û:ªY½à¼Æ¦r¬ü10147157µoªí®É¶¡:2023/2/10 ¤U¤È 09:29:21²Ä2894½g¦^À³
FDA¤w¸g¬°PRV³]¸m¸¨¤é±ø´Ú¡A September 30, 2024,¥H«á´NµLªkÂà°â¡A¨S¦³¤@»õ¬ü¤¸ªº»ù­È¤F

RPD Designation Program Sunset Provisions

On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any rare pediatric disease priority review vouchers.

For any questions, please contact the Office of Orphan Products Development at orphan@fda.hhs.gov.

·|­û:¤g¾|µf10147850µoªí®É¶¡:2023/2/10 ¤U¤È 08:35:33²Ä2893½g¦^À³
§Ú¸ò¤j®a¤À¨É¤@¤U, ¬Y®a¥h¦~¤W¿³ÂdªÑ²¼ªºªi§é:

³o®a¤½¥q¦¨¥ß9¦~¤~¤W¿³Âd. ­è¶}©l³o¤½¥q¦P®É¶i¦æ3¸ô²£«~½u. ¦P®É¤S¤À¤ß¥´ºâ°ê¥~¤W¥«.

µ²ªG3±ø½u³£°µ¤£¥X¦¨ªG. °ê¥~¤W¥«¤]®À§é. ®tÂI¸êª÷¬yÂ_Ãì.

«á¨Ó§ïÅÜ°µªk, ©ñ±ó2±ø²£«~½u. ±Mª`1±ø. ³o1²£«~½u¦³3ºØ¥\¯à, ¤]¥u±Mª`1ºØ. ¨M©w¥xÆW¤W¿³Âd,¥¼¨Ó¥xÆW¤WÂd.

µ²ªG¥h¦~¦¨¥\¤W¿³Âd. ªÑ¥»»P6634 ¬Û·í, ²£«~¥«³õ¤£¤Î6634 ªº¥i¯à1/3©Î1/4. ¥Ø«eªÑ»ù¥«6634ªº2­¿. ¸Ó¤½¥q²{¦b¥´ºâ2024 Q2±Mª`§¹¦¨2b.²{¦b¤w¸g¿n·¥½Í±ÂÅv. ¹w­pÁ{¤G§¹¦¨«á, ±ÂÅvª÷6-8.8»õ¬üª÷. ³Ì±ß2024Âà¤WÂd.

¦ÑÁó¸òªk¤H»¡·Q­n´X¦~«á(¤]³\10¦~), ±N¤½¥q¥H100»õ¬üª÷½æµ¹°ê¥~Ãļt.

µ²½×:

1.¥ý±Mª`³Ì©ú¬P²£«~.

2.¥þ¤O½Í±ÂÅv.

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2023/2/10 ¤U¤È 01:03:35²Ä2892½g¦^À³
¥HªYÄ£¥Ø«eªÑ»ù§ë¸ê°ò¥»¤Wºâ¬OÁÈ©w¤F¡F³Q¨ÖÁʾ÷²v¤£°ª¡A¦ý­n¦¬ÁʩΨÖÁÊ»ù°_½X­n¥Ø«eªÑ»ù3­¿¡F¥¿±`µo®i¤§¤U­Y­nªYÄ£¨«¨ìÅq®pªÑ»ù­n¦³5¦~ªø§ë¤ß²z¥´ºâ¡A´N¬O¬ãµo®É¶¡¦³´£«e­×§ï¡A¤´¬Oªø§ë¤~¯àÀò¤j§Q¡C
·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤U¤È 12:54:31²Ä2891½g¦^À³
www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=511915

©t¨àºÙ¸¹¡G ªvÀø±w¦³ÂX±i«¬¤ß¦Ù¯fªº¨à¬ì±wªÌ¡]0 ¦Ü 16 ·³¡^¡C

¤W¥«§å­ã¤é´Á¡G 2019-04-22

§å­ãªº¼ÐÅÒ¾AÀ³¯g¡G Corlanor ¾A¥Î©óªvÀø 6 ­Ó¤ë¤Î¥H¤WªºÄu©Ê¤ß«ß¦ñ¤ß²v¤É°ªªºÂX±i«¬¤ß¦Ù¯f (DCM) ¤Þ°_ªºÃ­©w¯gª¬©Ê¤ß¤O°IºÜ¡C

----------------------------------------------------------------------------------------------

¬JµMªvÀøÃh¥¥°ü¤kªº¯f¤Ó³Â·Ð¡A³o­ÓªvÀø¤p¨àDCM¯fÀ³¸Ó¬O¥i¥H¦a(¤£ª¾ªYÄ£§ä¹L¨S?)

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤U¤È 12:07:13²Ä2890½g¦^À³
±ÂÅv¤j«v°Ý!

¤µ¦~¤@­Ó¦³ÂI·N«äªº±ÂÅv®×¡A4­Ó¤ë¤@¨Ó¤@©¹®t»ù14»õ¬ü¤¸!

2023.1.25

www.drugtimes.cn/2023/01/25/yigelinchuangshiyandeshibaiweiasilikangshengxia14yimeiyuanci/

2018¦~¡A§A开¤F¤@®a¤½¥q¡A4¦~从¥¼¬Õ§Q¡AúÒ°µ¥X¤F¤@´Ú®Ö¤ß产«~¡C

¤@¦ì¤j¨Ð±oª¾¦Z¡A¦V§A´£¥X¦¬购¡]11亿¬ü¤¸¡^¡A§A¤£ªÖ¡A说钱¤£¤Óû{¡C

¤£¤[¦Z¡A§A带领¤½¥q¤W¥«¡Aú«­É®Ö¤ß产«~¡AªÑɲ¼É涨¡A¥«­È½µf¡C

¨º¦ì¤j¨Ð¦A¦¸§ä¨ì§A¡A¦A´£¦¬购¡A这¦¸¬O32亿¬ü¤¸¡A§A¤£ªÖ¡A说钱¤£¤Óû{¡C

¥i¦n´º¤£长¡A2个¤ë¦Z¡A§Aªº®Ö¤ß产«~¥X现问题¡A导­PªÑɲ¼É¶^¡A¥«­ÈÀþ间»]发ªñ¤@¥b¡C

还¬O¨º¦ì¤j¨Ð¡A还¬O¸ò§A´£¦¬购¡A¥u¤£过¥L这¦¸¥u­ã备¤F15亿¬ü¤¸¡A§AúÒ说¡A¥i¥H谈谈¡C

³Ì¦Z¡A§A们¥H18亿¬ü¤¸ªºÉ²®æ达¦¨¦X§@¡A¥|个¤ë¡A§A亏¤F14亿¬ü¤¸¡C

§A´N¬OCincor¡A¤@®a专ª`¤_难ªv©Ê°ª¦å压©MºC©Ê肾¯fªºBiotech¡C

¨º¦ì¤j¨Ð¡A¥sªü´µ§Q±d¡C

·|­û:´MÄ_10151381µoªí®É¶¡:2023/2/10 ¤U¤È 12:02:51²Ä2889½g¦^À³
©Ó¤U¡AÁÙ¬O§A·|¥Î±ÂÅv¤½¥q¥Ø«eªÑ»ù¥H¤Wªº2~3­¿»ù®æ¶i¦æªÑÅv¦¬ÁÊ¡H
·|­û:´MÄ_10151381µoªí®É¶¡:2023/2/10 ¤W¤È 11:53:57²Ä2888½g¦^À³
§Ú­Ì¥Î¤@­Ó«Ü²³æªºÅÞ¿è¥h·Q´N¦n¡A¦pªG§A¬O°ê»Ú¤jÃļt¡A§A·|Ä@·N¥Î10»õ¬üª÷¥H¤Wªºª÷ÃB¥h¨ú±o¤@®aªÑ²¼¥«­È¤£¨ì3»õ¬üª÷ªº¤½¥q±ÂÅv¦X¬ù¡H
·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 11:48:20²Ä2887½g¦^À³
Orphan drug©t¨àÃÄ!

18_Q&A_¤G´Á®³ÃÄÃÒ

www.facebook.com/100064104724409/videos/443452154155295?__so__=permalink

1¤À30¬í~ ­JP:§Ú­ÌÃĤ]¦b§V¤O¦a§ä...¥i¬O...§Ú­Ì«á¨Ó§ä¨ì¤@­ÓÃh¥¥°ü¤k¤~·|¦³ªº¯f §Ú­Ì´N¤£¸I ¦]¬°Ãh¥¥°ü¤k¤Ó³Â·Ð...

--------------------------------------------------------------------------------------------------

­JP»¡ªºÀ³¸Ó¬O:SNP-610¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x

CYP2E1ªvÀø¤p¨à¤ß¦Ù¯fÅÜ???

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 11:22:07²Ä2886½g¦^À³
¤°»ò¬OÂX±i©Ê¤ß¦Ù¯fÅÜ?

«ü¤ßŦ¦Ù¦×¥\¯à²§±`¡A¾É­P¤ßŦÂX¤j¦Ó¥B¤ß«Ç¦¬ÁY¥\¯àÅÜ®t¡A¬O[¤p¨à]¤ß¦Ù¯fÅܤ¤³Ì±`¨£ªº¤@ºØ¡C¤j³¡¤À¬°­ìµo©Ê¡A¤Ö³¡¤À¦]¨ä¥L¯e¯f¦Ó¤Þ°_¡C

-------------------------------------------------------------------------------------------------

­JP»¡­n§ä­Ó©t¨àÃľAÀ³¯g¥[³t¶}µo....¡A¦³¤H¤O´N±´¨sCYP2E1ªvÀø¤p¨à¤ß¦Ù¯fÅܬO­Ó¿ï¶µ!

¨ú±o¬ü°êFDAªº¡u¨u¨£¨à¬ì¯e¯f»{©w¡v¡]RPD¡^ªÌ¡A±N¯Ç¤J¬ü°êFDA¡uÀu¥ý¼f®Ö¾ÌÃÒ­pµe¡v¡A¦¹­pµe¦®¦b¹ªÀyÃļt¶}µo¨u¨£¨à¬ì¯e¯f¥ÎÃÄ¡AÀò¦¹»{©wªº·sÃÄ¡A¦bÀò­ã¤W¥««á§Y¥i¨ú±o¡uÀu¥ý¼f®Ö¾ÌÃÒ¡v¡]PRV¡^¡C---³o±i¾ÌÃÒ¥«»ù>1»õ¬ü¤¸!

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 11:14:02²Ä2885½g¦^À³
§Ú¨Æ«á½Ñ¸¯»¡¦a!
·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/10 ¤W¤È 11:06:08²Ä2884½g¦^À³
¥i¯à¬O¨S¦³°µ双ª¼¸ÕÅç

ÅçÃÒ©Ê2´Á

¦pªG¦³ÂI­pµeªº¸Ü

1´ÁÁö¬O¦w¥þ©Ê¸ÕÅç

ÁÙ¬O¥i¥H¦¬¶°¨ì¤@¨Ç·Q­nªº¥Í¤Æ«ü¼Æ

®Ú¾Ú³o¨Ç¸ê°T¥h³]­p2´Á

R¤j©Ò«üªº¡u²æ¿Ç¤l©ñ§¾¡v¤j·§¬O®Ú¥»¨S¦³¥²­n¥h°µ¨º­Ó2a¡C

106¦~´N­ã2´Á¡A¦³¥ø¹Ï¤ß¡A²{¦b³£¨ì3´Á¤F¡I

·|­û:¯È¤W´I¶Q10134993µoªí®É¶¡:2023/2/10 ¤W¤È 10:25:42²Ä2883½g¦^À³
­ì¨Ó¤§«e¤½§iªº2a¼Æ¾Ú¬O¾Ç³N¼Æ¾Ú

§Ú³£¨S¥D·N¨ì

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 09:57:01²Ä2882½g¦^À³
DCM 扩张«¬¤ß¦Ù¯f¬O¤@组进¦æ©Ê发®iªº严­«¤ß¦åºÞ¯e¯f¡A¨´¤µ¯Ê¥F¦³®Äªº针对©Êªv疗¡C

2021.12.18 cn.lillyasiaventures.com/blog/biomarin

¤E¤Ñ¥Íª«ÉO¬ü国BioMarin¨î药¤½¥q达¦¨¥þ²y战²¤¦X§@¡A为¤ß¦åºÞ¯e¯f开发创·s°ò¦]疗ªk

关¤_扩张«¬¤ß¦Ù¯f (DCM)

扩张«¬¤ß¦Ù¯f¬O导­P¤ß¤O°IºÜªº±`见­ì¦]¡A扩张«¬¤ß¦Ù¯f发®i¨ì¥½´Á±`»Ý­n¤ß脏²¾´Ó¡C尽ºÞ药ª«ªv疗©M护²z¦³©Ò§ïµ½¡A¦ý该¯e¯f 5 ¦~¥Í¦s²v约为 50%¡C¦b¬ü国¡B欧·ù¡B¤¤国©M¤é¥»µ¥¦a区¦³数¤QÉE±wªÌ¿©±w遗传©Ê扩张«¬¤ß¦Ù¯f¡C¬Û关¬ã¨s¤w发现 50 ¦h个¥i¯à导­P扩张«¬¤ß¦Ù¯fªº°ò¦]¬ð变¡A¥e®a±Ú©Ê扩张«¬¤ß¦Ù¯f¯f¨Òªº40-50%¡C¨ä¤¤¦³许¦h°ò¦]编码ªº³J¥Õ质¦b¤ß¦Ù细­M¤¤¨ã¦³­«­nªº¥\¯à¡A¥]¬A细­M°©¬[¡B¦Ù节©M®Ö¥]½¤³J¥Õ¡C§Ú们ªº¥Ø标¬O§Q¥Î°ò¦]ªv疗§Þ术纠¥¿这¨Ç导­PDCMªº遗传¦]¯À¡A针对¨C个¨ãÊ^¯e¯f¸Ñú¨¨ä®Ú¥»­P¯f­ì¦]¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 09:43:43²Ä2881½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2023/2/10 ¤W¤È 08:50:01²Ä 2876 ½g¦^À³

ªYÄ£¦b§í¨îCYP2E1¬O±j¶µ¡AÂX±i©Ê¤ß¦Ù¯fDCM¤]¦n¦nµo´§§a!(¾Ú§Ú­Ì©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É)

-------------------------------------------------------------------------------------------------

§Úªº¥Î·N¦bSNP-810±ÂÅv(§í¨îCYP2E1)®É¥i¯Ç¤J¦Ò¶q....(²¦³º¤§«e¨S¦³CYP2E1ªvÀø¤ßŦ¯fªº¬ã¨s)

¦ÓJ&J¥Î166»õ¬ü¤¸¦¬ÁÊAbiomed ¡A¹ï³o¶ô²j¯àµL¿³½ì!!!

·|­û:´MÄ_10151381µoªí®É¶¡:2023/2/10 ¤W¤È 09:34:24²Ä2880½g¦^À³
ªñ¨â¦~¨Ó¡A¶i¥X¨é°Ó¤¤´I¨¹¬Y¤ÀÂI¶R¶i¬ù1800±i¡]§¡»ù¦b81¤¸¥ª¥k¡^¡A¬Q¤é¨u¨£½æ¥X50±i¡A¬O§_¬O­Óĵ°T?
·|­û:¦V«e¦æ10140498µoªí®É¶¡:2023/2/10 ¤W¤È 09:31:05²Ä2879½g¦^À³
¯È¤j

¦n¹³¬Oºô­¶§ó·s«á¬Ý¨ìªº

810ªº³¡¤À¼g¤F¤@°ï

TO-R¤j

²{¶¥¬q³Ì«æ­¢ªº¥Ø¼Ð¡A¬OÃ@µ¦¤½¥q»°§Ö§¹¦¨810¡B610¸ÕÅç¡C

¤×¨ä¬O610¥Ø«e¬O¨«¦b®öÀY¤W

80¤Hªº¸ÕÅç¯u­n»°¶i«×¡A¦hµ¹Âå°|¼úª÷¡A3­Ó¤ë¥ÎÃÄ¡A«Ü§Ö´N·|§¹¦¨¡C

¤½¥qªº¦~³øÅã¥ÜM¤½¥q3´Á­n¨ì2024¦~¡A¤H®a2022/12´N¤½¥¬µ²ªG¡C

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 09:30:07²Ä2878½g¦^À³
¬d[SNP-610¬°SNP-630¦³®Ä¥NÁª«]¥i¨£
·|­û:¯È¤W´I¶Q10134993µoªí®É¶¡:2023/2/10 ¤W¤È 09:20:05²Ä2877½g¦^À³
SNP-610¬°SNP-630¦³®Ä¥NÁª«¡F²Ä¤@­ÓÁ{§É¤G´Á¾Ç³N®×©ó2021¦~§¹¦¨--¨ä¶¥¬q©Ê¥Øªº¤Î»ù­È¦b©ó§Ö³tÃÒ¹êÀø®Ä(¨Æ«á½Ñ¸¯:²{¦b¬Ý¬O²æ¿Ç¤l©ñ§¾¦h¦¹¤@Á|)

80¤H¬O¬dÅçµn°O¥ÎÁ{§É

------------------------------------------

½Ð°Ýr¤j³o¥y¸Ü¦b¦ó³B¬Ý¨ìªº©O¡H

·|­û:ROGER588910148151µoªí®É¶¡:2023/2/10 ¤W¤È 08:50:01²Ä2876½g¦^À³
ªYÄ£¦b§í¨îCYP2E1¬O±j¶µ¡AÂX±i©Ê¤ß¦Ù¯fDCM¤]¦n¦nµo´§§a!(¾Ú§Ú­Ì©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É)

2022.11.1 ¼b¥Í¤½¥q¥H166»õ¬ü¤¸¦¬ÁÊAbiomed ¥HÂX¤j¨ä¤ß¦åºÞ·~°È(°w¹ï«æ©Ê¤ßŦ°IºÜ±wªÌ´£¨Ñ¤ßŦ´_µd´`Àô¤ä«ù¤Î«ùÄò·ÓÅ@¤§ÂåÀø¾¹§÷ªº¬ã¨s¡B¶}µo¤Î¾P°â)

----------------------------------------------------------------------------------------------

1. 2019¦~ www.sciencedirect.com/science/article/pii/S0925443918303028

...³o¨Çµo²{­º¦¸´¦¥Ü Akt2 ¥\¯à¤£¥þ¥i¯à³q¹L CYP2E1 ¤¶¾Éªº¾÷¨î«P¶i¥NÁ©ʤߦٯfªºµo®i¡Aªí©ú CYP2E1 ¦b¥NÁ©ʤß

¦Ù¯fºÞ²z¤¤ªºªvÀø¼ç¤O¡C

2. 2021¦~ www.spandidos-publications.com/10.3892/mmr.2021.12492

...³o¨Çµo²{ÁÙªí©ú¡A§í¨î CYP2E1 ¥i¯à¬O±±¨î¤ßŦ¯fµo®iªº¤@ºØ¦³»ù­ÈªºªvÀøµ¦²¤¡A¤×¨ä¬O¨º¨Ç»P CYP2E1 ¤W½Õ¬ÛÃöªº¯e

¯f¡C

¦¹¥~¡A¥Ñ©ó CYP2E1 ¬O²Ó­M©M½u²ÉÅé ROS/RNS ªº¥D­n¨Ó·½¡A§í¨î CYP2E1 ¥i¯à·|§ïµ½ DCM ªº¯f²z¾v®i¡C¤W­z¬ã¨sªí©ú¡A§í¨îCYP2E1¥i¯à§ïµ½DCMªº¯f²z¾v®i¡ACYP2E1§í»s¾¯ªºÀ³¥Î¥i¯à¦¨¬°¤@ºØ¦³®ÄªºªvÀø¤â¬q¡FµM¦Ó¡A¾Ú§Ú­Ì©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É¡C

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:ªYÄ£¥ÍÂå
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!